{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:50:10Z","timestamp":1790607010271,"version":"4.1.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.phrs.2018.04.024","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T08:42:33Z","timestamp":1525077753000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review"],"prefix":"10.1016","volume":"133","author":[{"given":"Simona","family":"Guerzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Alberto","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.04.024_bib0005","doi-asserted-by":"crossref","first-page":"h1059","DOI":"10.1136\/bmj.h1059","article-title":"Guidelines, polypharmacy, and drug\u2013drug interactions in patients with multimorbidity","volume":"350","author":"Marengoni","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2018.04.024_bib0010","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Brunton","year":"2011"},{"key":"10.1016\/j.phrs.2018.04.024_bib0015","first-page":"546","article-title":"Drug interactions\u2013principles, examples and clinical consequences","volume":"109","author":"Cascorbi","year":"2012","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.phrs.2018.04.024_bib0020","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1553-2712.2000.tb00483.x","article-title":"Physician versus computer knowledge of potential drug interactions in the emergency department","author":"Langdorf","year":"2000","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.phrs.2018.04.024_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000365284","article-title":"Prevalence of and potential influencing factors for alcohol dependence in Europe","volume":"21","author":"Rehm","year":"2015","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.drugalcdep.2006.06.008","article-title":"Alcohol treatment utilization: findings from the national epidemiologic survey on alcohol and related conditions","volume":"86","author":"Cohen","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2018.04.024_bib0035","series-title":"Global Status Report on Alcohol and Health","author":"WHO","year":"2014"},{"key":"10.1016\/j.phrs.2018.04.024_bib0040","first-page":"VE01","article-title":"Alcohol withdrawal syndrome: benzodiazepines and beyond","volume":"9","author":"Sachdeva","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.35946\/arcr.v37.1.02","article-title":"Advances in medications and tailoring treatment for alcohol use disorder","volume":"37","author":"Seneviratne","year":"2015","journal-title":"Alcohol Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0050","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/acer.12357","article-title":"Alcohol medications development: advantages and caveats of government\/academia collaborating with the pharmaceutical industry","volume":"38","author":"Litten","year":"2014","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: a review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2018.04.024_bib0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2013","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2018.04.024_bib0065","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1360-0443.2011.03752.x","article-title":"Alcohol-dependence. The current French craze for baclofen","volume":"107","author":"Rolland","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2018.04.024_bib0070","first-page":"285","article-title":"Underutilization of pharmacotherapy for treatment of alcohol use disorders part II-results from a survey of practices among North Carolina mental health providers and brief review of efficacy of available pharmacotherapies","volume":"5","author":"Stanciu","year":"2017","journal-title":"J. Alcohol Drug Depend."},{"key":"10.1016\/j.phrs.2018.04.024_bib0075","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.64.5.566","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions","volume":"64","author":"Compton","year":"2007","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.phrs.2018.04.024_bib0080","first-page":"344","article-title":"FPIN\u2019s clinical inquiries. Management of alcohol withdrawal syndrome","volume":"82","author":"Ricks","year":"2010","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.phrs.2018.04.024_bib0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","article-title":"Pharmacological management of alcohol withdrawal. a meta-analysis and evidence-based practice guideline. american society of addiction medicine working group on pharmacological management of alcohol withdrawal","volume":"278","author":"Mayo-Smith","year":"1997","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2018.04.024_bib0090","first-page":"17","article-title":"H1 antihistamines and benzodiazepines. Pharmacological interactions and their impact on cerebral function","volume":"23","author":"Montoro","year":"2013","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/10401239509149041","article-title":"Delirium associated with clozapine and benzodiazepine combinations","volume":"7","author":"Jackson","year":"1995","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1300\/J069v14n01_04","article-title":"Pharmacotherapy in alcoholism","volume":"14","author":"Miller","year":"1995","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.phrs.2018.04.024_bib0105","doi-asserted-by":"crossref","first-page":"j1224","DOI":"10.1136\/bmj.j1224","article-title":"The growing problem of co-treatment with opioids and benzodiazepines","volume":"356","author":"Karaca-Mandic","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2018.04.024_bib0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2710.1998.00175.x","article-title":"Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants\u2013an update","author":"Tanaka","year":"1998","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","article-title":"Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines","volume":"32","author":"Fukasawa","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.2042-7158.2010.01176.x","article-title":"Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy","volume":"63","author":"Misaka","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00228-003-0681-4","article-title":"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers","volume":"59","author":"Oda","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-007-0350-0","article-title":"Voriconazole and fluconazole increase the exposure to oral diazepam","volume":"63","author":"Saari","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2125.2007.02970.x","article-title":"Interaction between midazolam and clarithromycin in the elderly","volume":"65","author":"Quinney","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0140","first-page":"577","article-title":"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics erythromycin, clarithromycin, and the azalide azithromycin","volume":"35","author":"Yeates","year":"1997","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","article-title":"Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe","volume":"74","author":"Majumdar","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s002280000156","article-title":"Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life","volume":"56","author":"Lilja","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1067\/mcp.2000.105757","article-title":"Alprazolam-ritonavir interaction: implications for product labeling","volume":"67","author":"Greenblatt","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0165","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/j.1875-9114.2011.01045.x","article-title":"Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy","volume":"32","author":"Hsu","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2018.04.024_bib0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin","volume":"37","author":"Backman","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2018.04.024_bib0175","first-page":"85S","article-title":"Factors influencing the activity and fate of benzodiazepines in the body","volume":"11","author":"van der Kleijn","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0180","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.111.043844","article-title":"Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro","volume":"40","author":"Keubler","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.04.024_bib0185","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00228-004-0855-8","article-title":"Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients","volume":"60","author":"Fellay","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0190","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1345\/aph.1C413","article-title":"Phenytoin-diazepam interaction","volume":"37","author":"Murphy","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2018.04.024_bib0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF03189827","article-title":"Musmul Interaction between grapefruit juice and diazepam in humans","volume":"23","author":"Ozdemir","year":"1998","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.04.024_bib0200","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2018.04.024_bib0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4212\/cjhp.v70i3.1656","article-title":"Pharmacokinetic interactions between valproic acid and lorazepam (PIVOtAL Study): a review of site-specific practices","volume":"70","author":"Tang","year":"2017","journal-title":"Can. J. Hosp. Pharm."},{"key":"10.1016\/j.phrs.2018.04.024_bib0210","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(80)90364-5","article-title":"Digoxin level and diazepam","volume":"2","author":"Castillo-Ferrando","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.04.024_bib0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00004714-199512000-00003","article-title":"Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam","volume":"15","author":"Greene","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0220","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00004714-199510000-00003","article-title":"Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam","volume":"15","author":"Barbhaiya","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.jcp.0000104908.75206.26","article-title":"Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers","volume":"24","author":"DeVane","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0230","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","article-title":"Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone","volume":"43","author":"Lam","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0235","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.2000.00271.x","article-title":"Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation","volume":"50","author":"Palovaara","year":"2000","journal-title":"Br. J. Clin Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0240","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/0091270009332435","article-title":"Effects of statins on the pharmacokinetics of midazolam in healthy volunteers","volume":"49","author":"Kokudai","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0245","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1530-0277.2008.00690.x","article-title":"Acamprosate: recent findings and future research directions","volume":"32","author":"Mann","year":"2008","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2004.03.004","article-title":"Biphasic effect of acamprosate on NMDA but not on GABA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network","volume":"47","author":"Pierrefiche","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2018.04.024_bib0255","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(96)00696-6","article-title":"The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal","volume":"317","author":"Putzke","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0260","unstructured":"No authors listed, New drug to treat alcoholism, FDA Consum. 38 (2004) 3."},{"key":"10.1016\/j.phrs.2018.04.024_bib0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcohol Clin Exp. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0270","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-015-0423-9","article-title":"Acamprosate: a review of its use in alcohol dependence","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2018.04.024_bib0275","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40264-016-0416-y","article-title":"Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence","volume":"39","author":"Sinclair","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2018.04.024_bib0280","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euroneuro.2003.08.009","article-title":"Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment","volume":"13","author":"Mason","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199835050-00001","article-title":"Clinical pharmacokinetics of acamprosate","volume":"35","author":"Saivin","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.04.024_bib0290","series-title":"Research of Pharmacokinetic Interactions Between Diazepam and Acamprosate when Given in Combination on Multiple Oral Dosing","author":"Fourtillan","year":"1995"},{"key":"10.1016\/j.phrs.2018.04.024_bib0295","series-title":"Research on Pharmacokinetic Interactions Between Imipramine and Acamprosate when Given in Combination on Multiple Oral Dosing","author":"Fourtillan","year":"1995"},{"key":"10.1016\/j.phrs.2018.04.024_bib0300","first-page":"25","article-title":"Tolerability of the combination of acamprosate with drugs used to prevent alcohol withdrawal syndrome","volume":"31","author":"Aubin","year":"1995","journal-title":"Alcoholism"},{"key":"10.1016\/j.phrs.2018.04.024_bib0305","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","article-title":"Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study","volume":"22","author":"Besson","year":"1998","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0310","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","article-title":"A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone","volume":"27","author":"Mason","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2018.04.024_bib0315","series-title":"Report of an Investigation of the Effect of Ethanol upon the Pharmacokinetics of Acamprosate","author":"Dewland","year":"1991"},{"key":"10.1016\/j.phrs.2018.04.024_bib0320","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0325","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.04.024_bib0330","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Baclofen Study Group, Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0335","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol Clin. Exp Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0340","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","volume":"49","author":"Morley","year":"2014","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0345","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/ags028","article-title":"Efficacy of high-dose baclofen in the treatment of alcoholics: a retrospective study at one year","volume":"47","author":"Rigal","year":"2012","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0350","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fpsyt.2012.00103","article-title":"Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients","volume":"3","author":"de Beaurepaire","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0355","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1360-0443.2011.03752.x","article-title":"Alcohol-dependence: the current French craze for baclofen","volume":"107","author":"Rolland","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2018.04.024_bib0360","first-page":"137","article-title":"Potentiation of opiates by administration of baclofen and proglumide during the intraoperative period","volume":"54","author":"Massei","year":"1988","journal-title":"Minerva Anestesiol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0365","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1213\/01.ANE.0000151717.74547.23","article-title":"Severe seizures during propofol induction in a patient with syringomyelia receiving baclofen","volume":"100","author":"Manikandan","year":"2005","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.phrs.2018.04.024_bib0370","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/brain\/awh181","article-title":"GABAA receptor dependent synchronization leads to ictogenesis in the human dysplastic cortex","volume":"127","author":"D\u2019Antuono","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2018.04.024_bib0375","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/AAP.0000000000000054","article-title":"Dyskinesia caused by ziconotide-baclofen combination in an adolescent affected by cerebral palsy","volume":"39","author":"Pozzi","year":"2014","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.phrs.2018.04.024_bib0380","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.1981.03320150019012","article-title":"Baclofen and tricyclic antidepressants: possible interaction","volume":"246","author":"Silverglat","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2018.04.024_bib0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1530-0277.2008.00805.x","article-title":"Acute interaction of baclofen in combination with alcohol in heavy social drinkers","volume":"33","author":"Evans","year":"2009","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0390","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","article-title":"Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation","volume":"25","author":"Rolland","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0395","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/alcalc\/ags076","article-title":"A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol","volume":"47","author":"Rolland","year":"2012","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0400","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/01952307.1992.11761520","article-title":"Clinical and pharmacokinetic aspects of high dose oral baclofen therapy","volume":"15","author":"Aisen","year":"1992","journal-title":"J. Am. Paraplegia Soc."},{"key":"10.1016\/j.phrs.2018.04.024_bib0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-9556(24)15277-4","article-title":"A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state","volume":"27","author":"Shellenberger","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.04.024_bib0410","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15288\/jsads.2014.75.79","article-title":"Pharmacotherapy of alcohol use disorders: seventy-five years of progress","volume":"75","author":"Zindel","year":"2014","journal-title":"J. Stud. Alcohol Drugs Suppl."},{"key":"10.1016\/j.phrs.2018.04.024_bib0415","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2011.05.015","article-title":"A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram","volume":"119","author":"Roache","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2018.04.024_bib0420","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/AC.67.4.2170696","article-title":"Intractable hypotension and myocardial ischaemia induced by co-ingestion of ethanol and disulfiram","volume":"67","author":"Moreels","year":"2012","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0425","first-page":"407","article-title":"A disulfiram-alcohol reaction after inhalation of a salbutamol aerosol: a plausible interaction?","volume":"58","author":"Choi","year":"2016","journal-title":"Tijdschr. Psychiatr."},{"key":"10.1016\/j.phrs.2018.04.024_bib0430","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/WNF.0000000000000166","article-title":"A case of disulfiram-Induced psychosis in a previously asymptomatic patient maintained on mixed amphetamine salts: a review of the literature and possible pathophysiological explanations","volume":"39","author":"Spiegel","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0435","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/08897077.2011.634968","article-title":"Psychosis induced by the interaction between disulfiram and methylphenidate may be dose dependent","volume":"33","author":"Grau-L\u00f3pez","year":"2012","journal-title":"Subst. Abus."},{"key":"10.1016\/j.phrs.2018.04.024_bib0440","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.159.2.297","article-title":"Buspirone-induced mania: possible interaction with disulfiram","volume":"159","author":"Iruela","year":"1991","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0445","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1176\/ajp.140.2.243","article-title":"Adverse interaction between disulfiram and marijuana: a case report","volume":"140","author":"Lacoursiere","year":"1983","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0450","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/clpt.1981.45","article-title":"Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin","volume":"29","author":"O'Reilly","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0455","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/ajp.125.12.1725","article-title":"Possible interaction between disulfiram and isoniazid","volume":"125","author":"Whittington","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0460","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/01.jcp.0000426185.68487.9a","article-title":"Psychotic symptoms after combined metronidazole-disulfiram use","volume":"33","author":"Luykx","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0465","first-page":"650","article-title":"The metabolism of halothane under the influence of thiopental methohexital, etomidate, enflurane and disulfiram under clinical conditions (author's transl)","volume":"29","author":"Scholler","year":"1980","journal-title":"Anaesthesist"},{"key":"10.1016\/j.phrs.2018.04.024_bib0470","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00000542-199903000-00019","article-title":"Clinical isoflurane metabolism by cytochrome P450 2E1","volume":"90","author":"Kharasch","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2018.04.024_bib0475","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/00000542-199506000-00009","article-title":"Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation","volume":"82","author":"Kharasch","year":"1995","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2018.04.024_bib0480","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/clpt.1989.61","article-title":"Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics","volume":"45","author":"Loi","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 369","key":"10.1016\/j.phrs.2018.04.024_bib0485","first-page":"59","article-title":"Disulfiram therapy \u2212 adverse drug reactions and interactions, Acta Psychiatr","volume":"86","author":"Enghusen Poulsen","year":"1992","journal-title":"Scand"},{"key":"10.1016\/j.phrs.2018.04.024_bib0490","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/archinte.162.4.474","article-title":"Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy","volume":"162","author":"Masi\u00e1","year":"2002","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.phrs.2018.04.024_bib0495","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0404.1981.tb00794.x","article-title":"Influence of disulfiram on the serum concentration of carbamazepine in patients with epilepsy","volume":"63","author":"Krag","year":"1981","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.phrs.2018.04.024_bib0500","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/cpt1978245583","article-title":"Interaction of disulfiram with benzodiazepines","volume":"24","author":"MacLeod","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0505","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.pnpbp.2009.06.019","article-title":"Potentially fatal interaction between colchicine and disulfiram","volume":"33","author":"Chen","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1521-0391.2013.12081.x","article-title":"Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism","volume":"23","author":"McCance-Katz","year":"2014","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.phrs.2018.04.024_bib0515","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archpsyc.1982.04290060083018","article-title":"Possible toxic interaction between disulfiram and amitriptyline","volume":"39","author":"Maany","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0520","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1176\/ajp.142.11.1373","article-title":"Pharmacokinetic interaction of disulfiram and antidepressants","volume":"142","author":"Ciraulo","year":"1985","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0525","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0196-0644(83)80516-2","article-title":"Delirium with phenytoin and disulfiram administration","volume":"12","author":"Brown","year":"1983","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.phrs.2018.04.024_bib0530","first-page":"93","article-title":"Mathematical analysis of a phenytoin-disulfiram interaction","volume":"38","author":"Taylor","year":"1981","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.phrs.2018.04.024_bib0535","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/j.1552-4604.1980.tb02543.x","article-title":"Methadone-disulfiram interaction during methadone maintenance","volume":"20","author":"Tong","year":"1980","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0540","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2165\/00003495-197713010-00003","article-title":"Drug interactions with oral sulphonylurea hypoglycaemic drugs","volume":"13","author":"Hansen","year":"1977","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2018.04.024_bib0545","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jama.1972.03190350052029","article-title":"Rifampin with disulfiram","volume":"219","author":"Rothstein","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2018.04.024_bib0550","unstructured":"European Medicines Agency (EMA). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002583\/WC500140255.pdf, 2017 (Accessed 30 November 2017)."},{"key":"10.1016\/j.phrs.2018.04.024_bib0555","series-title":"International Guide for Monitoring Alcohol Consumption and Related Harm","author":"World Health Organization, Department of Mental Health and Substance Dependence","year":"2000"},{"key":"10.1016\/j.phrs.2018.04.024_bib0560","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2013.03.002","article-title":"Naltrexone and nalmefene: any meaningful difference?","volume":"73","author":"Swift","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0565","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.conb.2013.05.005","article-title":"Pharmacotherapy for alcohol dependence: status of current treatments","volume":"23","author":"Franck","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0570","doi-asserted-by":"crossref","first-page":"e0129289","DOI":"10.1371\/journal.pone.0129289","article-title":"The effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcohol-dependent patients","volume":"10","author":"Fran\u00e7ois","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2018.04.024_bib0575","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2016.1146689","article-title":"Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential","volume":"17","author":"Soyka","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2018.04.024_bib0580","first-page":"19","article-title":"Neurobiology of alcohol and pharmacological aspects of Nalmefene","volume":"50","author":"Biggio","year":"2015","journal-title":"Riv. Psichiatr."},{"issue":"2015","key":"10.1016\/j.phrs.2018.04.024_bib0585","first-page":"1129","article-title":"Nalmefene and opioid withdrawal syndrome: analysis of the global pharmacovigilance database for adverse drug reactions","volume":"104","author":"Dahmke","year":"1994","journal-title":"Praxis (Bern)"},{"key":"10.1016\/j.phrs.2018.04.024_bib0590","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00228-015-1931-y","article-title":"R\u00e8seau des Centres Francais d\u2019Addictovigilance, Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction","volume":"71","author":"Diot","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0595","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0600","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/BF03256919","article-title":"Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study","volume":"31","author":"Matz","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.phrs.2018.04.024_bib0605","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","article-title":"Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety","volume":"37","author":"Litten","year":"2016","journal-title":"Subst. Abus."},{"key":"10.1016\/j.phrs.2018.04.024_bib0610","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2125.1996.04133.x","article-title":"The effect of age on the pharmacokinetics of the opioid antagonist Nalmefene","volume":"42","author":"Frye","year":"1996","journal-title":"Br. J. Clin Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0615","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bcp.12805","article-title":"Population pharmacokinetics of nalmefene in healthy subjects and its relation to (-opioid receptor occupancy","volume":"81","author":"Kyhl","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0620","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1530-0277.1994.tb00102.x","article-title":"Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject","volume":"18","author":"Salvato","year":"1994","journal-title":"Alcohol Clin. Exp Res."},{"key":"10.1016\/j.phrs.2018.04.024_bib0625","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0009-9236(97)90178-8","article-title":"Effects of liver disease on the disposition of the opioid antagonist nalmefene","volume":"61","author":"Frye","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0630","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/bdd.1933","article-title":"Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS\/MS","volume":"36","author":"Joo","year":"2015","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.phrs.2018.04.024_bib0635","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.106.009738","article-title":"Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode","volume":"34","author":"Takeda","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.04.024_bib0640","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) probes for human udp-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.04.024_bib0645","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/dmd.114.062380","article-title":"Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells","volume":"43","author":"Hu","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.04.024_bib0650","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/1475-2875-13-478","article-title":"The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine","volume":"13","author":"Zang","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.phrs.2018.04.024_bib0655","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fpsyt.2016.00182","article-title":"Pharmacotherapy for alcohol use disorders: physicians' perceptions and practices","volume":"7","author":"Ponce Martinez","year":"2016","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0660","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0740-5472(98)00039-7","article-title":"The effects of naltrexone on alcohol and cocaine use in dually addicted patients","volume":"16","author":"Oslin","year":"1999","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.phrs.2018.04.024_bib0665","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/adb.12425","article-title":"Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies","volume":"22","author":"Hendershot","year":"2017","journal-title":"Addict. Biol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0670","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2018.04.024_bib0675","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2515\/therapie\/2011072","article-title":"Naltrexone and opiate substitutive treatment","volume":"66","author":"Dupouy","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.phrs.2018.04.024_bib0680","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0750-7658(99)90217-4","article-title":"Interactions between naltrexone an opioid antagonist, and opioids administered during general anesthesia","volume":"18","author":"Tesson","year":"1999","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"10.1016\/j.phrs.2018.04.024_bib0685","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajem.2009.07.007","article-title":"First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug\u2013drug interaction","volume":"28","author":"Lemesle","year":"2010","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.phrs.2018.04.024_bib0690","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ajem.2017.04.012","article-title":"Potential drug interaction with opioid agonist in the setting of chronic low-dose opioid antagonist use","volume":"35","author":"Leonard","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.phrs.2018.04.024_bib0695","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/ajp.144.7.966b","article-title":"Interaction between thioridazine and naltrexone","volume":"144","author":"Maany","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2018.04.024_bib0700","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/13556219971551","article-title":"Electrocardiographic abnormalities during recovery from ultra-short opiate detoxification","volume":"4","author":"Allhoff","year":"1999","journal-title":"Addict. Biol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0705","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/jcp.0b13e3180337fcb","article-title":"VA VISN I MIRECC Study Group, Naltrexone and disulfiram in patients with alcohol dependence and current depression","volume":"27","author":"Petrakis","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0710","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","article-title":"An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A","volume":"9","author":"Attarian","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2018.04.024_bib0715","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0091270011403740","article-title":"Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules","volume":"52","author":"Johnson","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0720","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2125.2000.00281.x","article-title":"Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol","volume":"50","author":"Porter","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0725","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/JCP.0000000000000373","article-title":"Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability","volume":"35","author":"Turel","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0730","first-page":"CD010410","article-title":"Low dose naltrexone for induction of remission in Crohn's disease","volume":"2","author":"Segal","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2018.04.024_bib0735","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/add.13753","article-title":"CTN-0055 CHOICES Investigators, Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot\/feasibility randomized trial","volume":"112","author":"Korthuis","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2018.04.024_bib0740","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1521-0391.2001.tb00519.x","article-title":"Effect of opioid dependence pharmacotherapies on zidovudine disposition","volume":"10","author":"McCance-Katz","year":"2001","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.phrs.2018.04.024_bib0745","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0005-7967(98)00100-4","article-title":"No interactive effects of naltrexone and benzodiazepines on pain during phobic fear","volume":"37","author":"Janssen","year":"1999","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.phrs.2018.04.024_bib0750","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.lfs.2005.05.036","article-title":"Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients","volume":"77","author":"Stella","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2018.04.024_bib0755","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/JCP.0000000000000287","article-title":"A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression","volume":"35","author":"Adamson","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2018.04.024_bib0760","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.drugalcdep.2008.06.006","article-title":"A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence","volume":"99","author":"Farren","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2018.04.024_bib0765","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00139709-200423010-00002","article-title":"Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug","volume":"23","author":"Wong","year":"2004","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.phrs.2018.04.024_bib0770","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2174\/138161210791516468","article-title":"Medications acting on the GABA system in the treatment of alcoholic patients","volume":"16","author":"Caputo","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2018.04.024_bib0775","first-page":"4654","article-title":"Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome","volume":"19","author":"Busard\u00f2","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2018.04.024_bib0780","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0741-8329(99)00085-3","article-title":"Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence","volume":"20","author":"Begh\u00e8","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.phrs.2018.04.024_bib0785","unstructured":"G.L. Pharma GmbH. Alcover\u00ae (sodium gamma hydroxybutyric acid): Austrian summary of product characteristics. 2012."},{"key":"10.1016\/j.phrs.2018.04.024_bib0790","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881108094620","article-title":"Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study","volume":"23","author":"Caputo","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0795","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/ijerph8072816","article-title":"Long-term \u03b3-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics","volume":"8","author":"Maremmani","year":"2011","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"10.1016\/j.phrs.2018.04.024_bib0800","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","article-title":"Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence","volume":"34","author":"Keating","year":"2014","journal-title":"Clin. Drug. Investig."},{"key":"10.1016\/j.phrs.2018.04.024_bib0805","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","article-title":"GHB and ethanol effects and interactions in humans","volume":"26","author":"Thai","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0810","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bcp.12632","article-title":"Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers","volume":"80","author":"Pross","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0815","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0820","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","article-title":"Gamma-hydroxybutyrate and ethanol effects and interactions in humans","volume":"26","author":"Thai","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0825","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug\u2013drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0830","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00228-012-1450-z","article-title":"Gamma-hydroxybutyrate (GHB) and topiramate?clinically relevant drug interaction suggested by a case of coma and increased plasma GHB concentration","volume":"69","author":"Weiss","year":"2013","journal-title":"Eur. J. Clin Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.024_bib0835","first-page":"1","article-title":"Alcohol addiction \u2212 the safety of available approved treatment options","volume":"20","author":"Antonelli","year":"2017","journal-title":"Expert Opin Drug. Saf."},{"key":"10.1016\/j.phrs.2018.04.024_bib0840","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40263-016-0403-y","article-title":"Diazepam in the treatment of moderate to severe alcohol withdrawal","volume":"31","author":"Weintraub","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2018.04.024_bib0845","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/02791072.1988.10472495","article-title":"The clinical use of disulfiram (Antabuse\u00ae): A review","volume":"20","author":"Banys","year":"1988","journal-title":"J. Psychoact. Drugs"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181731678X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181731678X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:55:05Z","timestamp":1760910905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181731678X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":169,"alternative-id":["S104366181731678X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.024","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}